WO2009112539A2 - Fermeture - Google Patents

Fermeture Download PDF

Info

Publication number
WO2009112539A2
WO2009112539A2 PCT/EP2009/052892 EP2009052892W WO2009112539A2 WO 2009112539 A2 WO2009112539 A2 WO 2009112539A2 EP 2009052892 W EP2009052892 W EP 2009052892W WO 2009112539 A2 WO2009112539 A2 WO 2009112539A2
Authority
WO
WIPO (PCT)
Prior art keywords
closure
article
opening
figures
count
Prior art date
Application number
PCT/EP2009/052892
Other languages
English (en)
Other versions
WO2009112539A3 (fr
Inventor
Joseph Paul Marino Jr
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of WO2009112539A2 publication Critical patent/WO2009112539A2/fr
Publication of WO2009112539A3 publication Critical patent/WO2009112539A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0025—Mouthpieces therefor with caps
    • A61M15/0026—Hinged caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/007—Mechanical counters
    • A61M15/0071—Mechanical counters having a display or indicator
    • A61M15/0075—Mechanical counters having a display or indicator on a disc
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/0081—Locking means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/82—Internal energy supply devices
    • A61M2205/8275—Mechanical
    • A61M2205/8281—Mechanical spring operated
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
    • B65D83/38—Details of the container body
    • B65D83/384—Details of the container body comprising an aerosol container disposed in an outer shell or in an external container
    • B65D83/386—Details of the container body comprising an aerosol container disposed in an outer shell or in an external container actuation occurring by moving the aerosol container relative to the outer shell or external container

Definitions

  • the obstruction obstructs movement of the closure when the closure and connector parts move in unison in the opening direction.
  • Figure 6 shows a schematic view of part of the internal mechanism of the drug dispenser device of Figure 1 with front plate removed, and in particular, the 'interlock' mechanism provided to block actuation thereof when the mouthpiece is covered by the mouthpiece cover;
  • Figure 7 shows a perspective view of the drug dispenser device of Figure 1 with the mouthpiece cover removed from the mouthpiece and thus, in a 'ready to use' position;
  • Figure 9 illustrates a perspective view of a first half of the drug dispenser of Figure 1 showing air flow into the housing in the 'in use' position thereof;
  • Figure 10 illustrates a perspective cut-away view of a second half of the drug dispenser device of Figure 1 (with actuation counter and details of internal mechanism omitted) showing air flow through the chambers of the housing in the 'in use' position thereof;
  • Figure 1 1 illustrates a perspective cut-away view of a second half of a drug dispenser device that is a slight variation of that drug dispenser device of Figure 1 (with actuation counter and details of internal mechanism omitted) showing air flow through the inhaler body in the 'in use' position thereof;
  • Figures 14a and 14b show cut-away views of the actuation counter of Figure 12 at respectively 'count 120' and 'count 119' positions;
  • Figure 19 shows a front view of the drug dispenser device of Figure 1 with upper front cover part and actuation counter removed, the device being in the 'at rest' position;
  • FIGS 36a to 36o respectively show front views of further alternative mouthpiece forms which may be employed in the drug dispenser devices of Figures 1 and 11 as an alternative to the mouthpieces thereof;
  • the container collar 30 permanently engages via split-ring collar 33 with the neck 5a of the canister 5 such that the so-engaged parts are moveable together relative to the housing in a direction defined by the longitudinal axis L-L of the canister 5 (i.e. generally up and down when the device 1 is upright).
  • the split-ring collar 33 permanently engages the container collar 30 to the canister 5 as described in US patent application Nos. 10/110,611 (WO-A-01/28887) and US-A-2006/0082039, hereby incorporated herein by reference.
  • each foot 35a, 35b is slightly spaced from its respective step 18a, 18b on the housing.
  • a third flexible support leg (not visible, but associated with third step 18c as visible on Figure 28) locates at the rear of the container collar (i.e. there are three flexible support legs 34a, 34b).
  • the two support legs 34a, 34b on either side of the mouthpiece 14 are spaced at 1 13.4° intervals relative to a third support leg (not visible) which locates rearwards to the mouthpiece 14.
  • ramps 44 provided to the extension collar 40 respectively engage with the shaped heads 36a, 36b of the flexible legs 34a, 34b and act on the already-tensed flexible legs 34a, 34b such that each foot thereof 35a, 35b is at the point of becoming displaced from its respective step 18a, 18b.
  • the ramp 44 acts to 'guide' the displacement action.
  • Figure 4b corresponds to the position at which the latching engagement of the flexible legs 34a, 34b with their steps 18a, 18b is just about to be overcome for release of the biasing energy stored in the extension springs 50a, 50b.
  • closure and connector parts 716a, b are coupled whereby, as shown in Figure 38c, further onward movement of the closure part 716a in the opening direction O causes the closure and connector parts 716a, b to rotate in unison in the opening direction O. This results in the closure part 716a further opening the mouthpiece 14 and rotation of the interference elements 717a, 717b towards an unlocking position where they will no longer block downward movement of the container collar 30 through blocking interaction with the downward protrusions 38a, 38b thereof.
  • the delivery channel 74 is a tapering channel which narrows towards the spray orifice 72.
  • the delivery channel 74 has straight wall sections.
  • the spray orifice 172 may be centrally located in the circular arrangement of the air holes 166. As may be seen in Figure 11 , when external air 160a is drawn through these plural spaced air holes 166 a plurality of air flows 162 is defined within the mouthpiece 114. This provides for an essentially annular air flow at the inner peripheral surface of the mouthpiece 1 14, which essentially sheaths the aerosol spray 164 as delivered from the spray orifice 172 of the nozzle outlet 170, thereby entraining the aerosol spray and reducing deposition at the internal surface of the mouthpiece 114.
  • the actuation counter 201 is comprised within upper front part 10a of the drug dispenser device 1 (or 101 ) which provides first 212 and second 214 spindle mountings, each capable of defining an axis of rotation, and a circumferential wall 218 defining a bezel form retainer 219.
  • a viewing window 216 is provided to the housing to enable the viewing of the count.
  • the oval-shaped front face 101 of the upper front part 10a is covered with a correspondingly shaped label 103 (e.g. of a polymeric material) to cover the apertures in the front face 101 shown in Figure 13b, but not the viewing window 216.
  • the label has an aperture 105 which registers with the viewing window 216.
  • the label 103 may itself have a transparent portion in place of the aperture 105 to enable observation of the viewing window 216.
  • the second count wheel 230 is integrally formed with the shutter portion 280.
  • the indentations 236 in this embodiment have a symmetrical shape, more particularly a generally U-shape. However, other shapes could be used. Moreover, asymmetric shapes could also be used. For instance, it may be useful for the flanks of the indentations 236 to present different angles, for example for the trailing (rear) flanks of the indentations 236 (relative to the direction of rotation of the second count wheel 230, e.g. anti-clockwise in Figures 14a and 14b) to form a greater angle with a central radial line through the indentations 236 than the leading (forward) flanks. This means there is less resistance to the pawl 217 releasing from the indentations 236 as the second count wheel 230 is driven by the kick wheel 240.
  • the components of the actuation counter 201 and any assemblies and sub- assemblies described above may be made from any suitable materials such as plastic polymer materials (e.g. acetal or ABS or styrene polymers).
  • the count wheels 220, 230 may be of ABS while the kick wheel 240 and the ratchet wheel 250 may be of acetal.
  • Figures 31 a and 31 b respectively show back and front views of a front plate 690 (hereinafter in the description of this modification the "driver plate") for use with a modified version 601 of the actuation counter 201 of Figures 12 to 21.
  • the modified actuation counter 601 will be appreciated to have a generally similar mode of usage to that of the unmodified counter 201 , but also includes features to prevent 'overrun' of the count. The operation of the modified counter 601 is described below in more detail with reference to Figures 32a to 35b.
  • Figures 34a and 34b respectively show perspective underside and top views of the first count wheel 620 for use in the modified actuation counter 601.
  • discshaped first count wheel 620 has 'units' (i.e. numerals) count indicia 622 provided at spaced intervals on a top face thereof.
  • Alignment holes 622a, 622b and notches 622e, 662f are provided adjacent indicia '6' and 7' and '8' and '9' respectively, and also alignment holes 622c, 622d adjacent indicia '3' and '8' for alignment of the first count wheel 620 with the second count wheel 630 during assembly of the counter 601.
  • the first count wheel 620 is provided with a central aperture 626 and a circular cavity 623 that is arranged for disposed receipt of ratchet wheel 250 (not shown, but see e.g. Figures 12 and 21 ).
  • Ratchet drive receipt teeth 624 are arranged about the inner circumferential wall 625 of the cavity for ratcheted drive interaction with the ratchet wheel 250.
  • the ratchet wheel 250 itself, is sized and shaped for receipt by the circular cavity 623 of the first count wheel 620 and is provided with two oppositely-located drive tongues 252a, 252b for ratcheted drive interaction with the ratchet drive receipt teeth 224.
  • FIG. 22 Details of the container collar 330 of the alternative internal mechanism are shown at Figures 22 and 23. Details of the extension collar 340 of the alternative internal mechanism are shown at Figures 24 and 25. Assembly steps relating to the alternative internal mechanism are illustrated at Figures 26a to 26c, and key operational aspects at Figures 27a to 27c.
  • the split-ring collar 333 which generally comprises a plastic polymer material, is used to permanently fix the container collar 330 to the neck 305a of the canister 305 by ultrasonic welding, as generally described in US patent application Nos. 10/110,611 (WO-A-01/28887) and US-A-2006/0082039.
  • Figures 27a to 27c illustrate details of the relationship between a flexible support leg 334a of container collar 330 and an inner 343 and outer ramp 344 of the extension collar 340 during operation of the device 1.
  • Figure 27a shows details of this relationship when the device 1 is in the 'at rest' position (i.e. corresponding to previous Figure 3a). That is to say, with no downward force applied by the levers 20a, 20b to the shelf 342 of the extension collar 340.
  • the flexible support leg 334a of the container collar 330 protrudes down between the inner 343 and outer 344 ramps of the extension collar 340, and interacts at its bottom end with a respective step 18a, 18b on the housing.
  • Figure 27b shows details of this relationship when the device 1 is in a 'tipping point' configuration (i.e. roughly corresponding to previous Figure 4c).
  • Figure 27b shows details of this relationship when the device 1 is in a 'tipping point' configuration (i.e. roughly corresponding to previous Figure 4c).
  • significant downward force has been applied by the levers 20a, 20b of the device 1 to the shelf 342 of the extension collar 340.
  • the outer ramp 344 of the extension collar 340 has been brought down on the protruding outer foot 336a of the flexible leg support 334a, thereby causing the flexible leg support 334a to flex inwards and to be displaced interiorly to the outer ramp 344.
  • the coiled coil extension springs 350a return to their 'at rest' state (i.e. with no externally-applied biasing energy, but only any initial biasing tension inherent in the closed coil form of the extension springs 350a present).
  • the return spring (not shown) of the valve 306 of the valved canister 305 provides energy to move the canister 305, container collar 330, extension collar 340 and levers 20a, 20b back to the 'at rest' position.
  • closure and connector parts 916a, 916b may again be formed respectively from ABS and polypropylene (PP).
  • antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine
  • antihistamines e.g., methapyrilene
  • anti- inflammatories e.g., beclomethasone (e.g. as the dipropionate ester), fluticasone (e.g. as the propionate or furoate ester), flunisolide, budesonide, rofleponide, mometasone e.g. as the furoate ester), ciclesonide, triamcinolone (e.g.
  • H1 antagonists include, without limitation, amelexanox, astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, levocetirizine, efletirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, mizolastine, mequitazine, mianserin, noberastine, meclizine, norastemizole, olopatadine, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, warmth and
  • the drug formulations are preferably substantially free of chlorofluorocarbons such as CCI 3 F, CCI 2 F 2 and CF 3 CCI 3 .
  • the propellant is liquefied HFA134a or
  • a surfactant may also be employed in the aerosol formulation.
  • Examples of conventional surfactants are disclosed in EP-A-372,777.
  • the amount of surfactant employed is desirable in the range 0.0001% to 50% weight to weight ratio relative to the drug, in particular, 0.05 to 10% weight to weight ratio.
  • Suitable solution formulations may also comprise one or more of the following components: viscosity enhancing agents; preservatives; and isotonicity adjusting agents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Un aspect de l’invention concerne une fermeture 716 destinée à être utilisée avec un article 1 présentant une évacuation 14. La fermeture comprend une partie de fermeture 716a permettant de fermer l’évacuation, une partie de liaison 716b permettant de relier la fermeture à l'article, et une articulation 719 entre les parties de fermeture et de liaison permettant à la partie de fermeture d'être articulée par rapport à la partie de liaison. La fermeture est configurée et disposée de sorte que l'articulation de la partie de fermeture par rapport à la partie de liaison dans une direction d'ouverture O présente la limite suivante : la partie de fermeture est accouplée à la partie de liaison de sorte que les parties de fermeture et de liaison doivent ensuite se déplacer ensemble dans la direction d'ouverture.
PCT/EP2009/052892 2008-03-12 2009-03-12 Fermeture WO2009112539A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3587208P 2008-03-12 2008-03-12
US61/035,872 2008-03-12

Publications (2)

Publication Number Publication Date
WO2009112539A2 true WO2009112539A2 (fr) 2009-09-17
WO2009112539A3 WO2009112539A3 (fr) 2009-11-19

Family

ID=40718646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/052892 WO2009112539A2 (fr) 2008-03-12 2009-03-12 Fermeture

Country Status (1)

Country Link
WO (1) WO2009112539A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9179691B2 (en) 2007-12-14 2015-11-10 Aerodesigns, Inc. Delivering aerosolizable food products

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2312379A (en) * 1996-04-25 1997-10-29 Bespak Plc Metered dose inhaler
WO2005046774A1 (fr) * 2003-11-17 2005-05-26 Astrazeneca Ab Courroie pour bouchon d'inhalateur
WO2005087299A1 (fr) * 2004-03-10 2005-09-22 Glaxo Group Limited Dispositif de distribution
WO2006097756A1 (fr) * 2005-03-17 2006-09-21 Glaxo Group Limited Inhalateurs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2312379A (en) * 1996-04-25 1997-10-29 Bespak Plc Metered dose inhaler
WO2005046774A1 (fr) * 2003-11-17 2005-05-26 Astrazeneca Ab Courroie pour bouchon d'inhalateur
WO2005087299A1 (fr) * 2004-03-10 2005-09-22 Glaxo Group Limited Dispositif de distribution
WO2006097756A1 (fr) * 2005-03-17 2006-09-21 Glaxo Group Limited Inhalateurs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9179691B2 (en) 2007-12-14 2015-11-10 Aerodesigns, Inc. Delivering aerosolizable food products

Also Published As

Publication number Publication date
WO2009112539A3 (fr) 2009-11-19

Similar Documents

Publication Publication Date Title
US9327088B2 (en) Drug dispenser
US8656911B2 (en) Actuation counter
US8820318B2 (en) Drug dispenser
EP2061604B1 (fr) Distributeur de médicaments
US8590529B2 (en) Actuator for an inhaler
US20100218760A1 (en) Actuator for an inhaler
WO2008110584A2 (fr) Distributeur de médicament
US20110259323A1 (en) Actuator for an inhaler
US20100275909A1 (en) Actuator for an inhaler
WO2009112539A2 (fr) Fermeture

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09720979

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A)

122 Ep: pct application non-entry in european phase

Ref document number: 09720979

Country of ref document: EP

Kind code of ref document: A2